参考文献/References:
[1] Powers William J,Rabinstein Alejandro A,Ackerson Teri, et al.2018 Guidelines for the early management of patients with acute ischemic stroke:A guideline for healthcare professionals from the heart association/american stroke association[J].Stroke,2018,49(3):e46-e110.
[2] Mccullough PA,Vasudevan A,Mohanakrishnan S,et al.Urinary 11-Dehydro-Thromboxane B and mortality in patients with stable coronary artery disease[J].J Cardiol,2017,119(7):972-977.
[3] Halawani SH,Williams DJ,Webster JA,et al.Aspirin failure in patients presenting with acute cerebrovascular ischaemia[J].Thromb Haemost,2011,106(2):240-247.
[4] Divani AA,Zantek ND,Borhani-Haghighi A,et al.Antiplatelet therapy:aspirin resistance and all that jazz![J].Clin Appl Thromb Hemost,2012,19(1):5-18.
[5] Mason PJ,Jacobs AK,Freedman JE.Aspirin resistance and atherothrombotic disease[J].J Am Coll Cardiol,2005,46(6):986-993.
[6] Zhang N,Wang ZH,Zhou LH.Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke[J].Brain Res Bull,2017,134(7329):205-210.
[7] Lopez LR,Guyer KE,Torre Ignacio Garcia De La,et al.Platelet thromboxane(11-dehydro-Thromboxane B2)and aspirin response in patients with diabetes and coronary artery disease[J].World J Diabetes,2014,5(2):115-127.
[8] Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ, 2002,324:71-86.
[9] Norgard NB.Obesity and altered aspirin pharmacology[J].Clin Pharmacokinet,2018,57(6):663-672.
[10] Pakottke-Marchant PK,Poggio ED.Profile andprevalence of aspirin resistance in patients with cardiovasculardisease[J].Am J Cardiol,2001,88(3):230-235.
[11] Weber AA,Przytulski B,Schanz A,et al.Towards a definition of aspirin resistance:a typological approach[J].Platelets,2002,13(1):37-40.
[12] Tseeng S,Arora R.Aspirin resistance:Biological and clinical implications[J].J Cardiovasc Pharmacol Ther,2008,13(1):5-12.
[13] Svenstrup PT,Kristensen SR,Atar D,et al.A critical appraisal of the phenomenon of aspirin resistance[J].Cardiology,2005,104(2):83-91.
[14] Chamorro Angel. TP receptor antagonism:a new concept in atherothrombosis and stroke prevention[J].Cerebrovasc Dis,2009,27(Suppl 3):20-27.
[15] 顾永丽,孙增先.阿司匹林抵抗与氯吡格雷抵抗的研究进展[J].中国医院药学杂志,2016,36(10):866-869.
[16] 杨昊翔,尹立勇,于丹军,等.阿司匹林抵抗与缺血性脑卒中复发相关性研究[J].临床军医杂志,2017,45(9):957-959.
[17] El-Mitwalli A,Azzam H,Abu-Hegazy M,et al.Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia[J].Clin Neurol Neurosurg,2013,115(7):944-947.
[18] Englyst NA,Horsfield G,Kwan J,et al.Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity[J].Journal of Cerebral Blood Flow and Metabolism,2008,28(6):1196-1203.
[19] 刘敏,邹晓,李建华,等.老年代谢综合征患者阿司匹林抵抗与平均血小板体积和收缩压的相关性研究[J].中华老年心脑血管病杂志,2016,18(08):815-818.
[20] Chadha D S, Sumana Budha, Karthikeyan Ganesan, et al.Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease[J].Catheter Cardiovasc Interv,2016,88(4):e126-e131.
[21] 柯瑟章,邹晓,孙玉发,等.老年高血压患者阿司匹林抵抗的现患率和危险因素调查[J].中华老年心脑血管病杂志,2017,19(4):366-369.
[22] Pettersen AA,Amesen H,Seljeflot I.A brief review on high on-aspirin residual platelet reactivity[J].Vascul Pharmacol,2015,67-69:6-9.
[23] Derle E,Ocal R,Kibaroglu S,et al.Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients[J].Blood Coagulation & Fibrinolysis,2016,27(2):169-175.
[24] Colaizzo D,Fofi L,Tiscia G,et al.The COX-2 G/C-765 polymorphism May modulate the occurrence of cerebrovascular ischemia[J].Blood Coagulation & Fibrinolysis,2006,17(2):93-96.
[25] Wang H,Sun X,Dong W,et al.Association of GPIa and COX-2 gene polymorphism with aspirin resistance[J].J Clin Lab Anal,2018,32(4):e22331.
[26] Fitzgerald R,Pirmohamed M.Aspirin resistance:effect of clinical, biochemical and genetic factors[J].Pharmacol Ther,2011,130(2):213-225.
[27] Weng ZY,Li XB,Li YQ,et al.The association of four common polymorphisms from four candidate genes(COX-1, COX-2, ITGA2B, ITGA2)with aspirin insensitivity:a Meta-Analysis[J].PLoS One,2013,8(11):e78093.
[28] Du G,Lin Q,Wang JH.A brief review on the mechanisms of aspirin resistance[J].Int J Cardiol,2016,220:21-26.
[29] Floyd CN,Ferro A.Mechanisms of aspirin resistance[J].Pharmacol Ther,2014,141(1):69-78.
[30] 黄亚,闫福岭.阿司匹林抵抗研究进展[J].东南大学学报(医学版),2015,34(3):459-462.
[31] McCullough Peter A, Vasudevan Anupama, Lopez Luis R, et al.Oxidative stress reflected by increased F-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B levels in patients with coronary artery disease[J].Thromb Res,2016,148:85-88.
[32] Dharmasaroja PA,Sae-Lim S.Comparison of aspirin response measured by urinary 11-Dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke[J].Journal of Stroke & Cerebrovascular Diseases,2014,23(5):953-957.
[33] Wang CW,Su LL,Hua QJ,et al.Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients[J].Brain Res Bull,2018,142:176-182.
[34] Yi XY,Wang C,Liu P,et al.Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population[J].J Neurol,2016,263(8):1612-1619.
[35] Cheng X,Xie NC,Xu HL,et al.Biochemical aspirin resistance is associated with increased stroke severity and infarct volumes in ischemic stroke patients[J].Oncotarget,2017,8(44):77086-77095.
[36] Gengo Fran,Westphal Erica S,Rainka Michelle, M et al.Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg[J].J Clin Pharmacol,2016,56(4):414-421.
[37] 王彦喆,何志义.阿司匹林抵抗与脑卒中防治的现状[J].中华脑科疾病与康复杂志(电子版),2014,4(4):212-217.
[38] Johnston SC,Easton JD,Farrant MA,et al.Clopidogrel and aspirin in acute ischemic stroke and High-Risk TIA[J].N Engl J Med,2018,379(3):215-225.
[39] Bhatt Deepak L. My Approach to the patient with CAD and aspirin resistance[J].Trends Cardiovasc.Med,2017,27(7):518-519.
[40] 黄引怀,董春玲,邹雅敏,等.浅谈阿司匹林抵抗的临床防治措施[J].北方药学,2017,14(11):146-147.